David Harris, David Kalir, Cory Chevalier, Krista Dobbie, Flannery Fielding, Ruth Lagman, Ahed Makhoul, Susan McInnes, Sina Najafi, Kyle Neale, Lisa Rybicki, Melanie Robbins-Ong, Kathleen Neuendorf
Context: Methylnaltrexone is a peripherally-acting mu-opioid receptor antagonist studied in both cancer and non-cancer patients with opioid-induced constipation (OIC), but mostly in the outpatient setting. For adult hospitalized cancer patients with OIC, its effectiveness is unknown. Objectives: Describe the efficacy of methylnaltrexone for OIC in the inpatient setting, defined as bowel movement (BM) within 24 hours of methylnaltrexone administration. Methods: We performed a single-center, retrospective chart review of all hospitalized, adult patients with a cancer diagnosis who received methylnaltrexone from the palliative care team between January 1st, 2012 and July 1st, 2019...
December 24, 2022: American Journal of Hospice & Palliative Care